CADL Financials: Candel Therapeutics Inc AI Analysis



Financials

CADL Financial

Candel Therapeutics Inc

$8.77

-1.57%

$-0.14

At close: May 15, 16:00:00 GMT-4

$8.93

1.92%

$0.16

Post-market: May 15, 19:57:34 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$8.91

Open

$8.67

Day's Range

$7.78 - $9.07

52 week range

$4.33 - $8.93

Volume

3.6M

Avg.Volume

1.2M

Dividend yield

EPS (TTM)

-0.70

Market Cap

$654.7M

What is CADL?

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Features

Markets

News

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	17	4	4	4	4	3
Research & Development	29	10	7	6	3	4
Operating Expenses	47	15	12	11	8	8
Other Non Operating Income (Expenses)	8	-13	1	5	14	-5
Pretax Income	-38	-29	-11	-4	7	-14
Income Tax Expense	--	--	--	--	--	0
Net Income	-38	-29	-11	-4	7	-14
Net Income Growth	-31%	107%	10%	-82%	-188%	27%
Shares Outstanding (Diluted)	54.91	54.91	54.89	51.48	54.76	35.59
Shares Change (YoY)	54%	54%	71%	72%	88%	23%
EPS (Diluted)	-0.7	-0.53	-0.2	-0.09	0.13	-0.4
EPS Growth	-55%	34%	-38%	-87%	-148%	5%
Free Cash Flow	-38	-10	-10	-8	-8	-5
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-47	-15	-12	-11	-8	-8
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-47	-15	-12	-11	-8	-8
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	--	--	--	0%

Breakdown

TTM

12/31/2025

09/30/2025

06/30/2025

03/31/2025

12/31/2024

Revenue

Revenue Growth (YoY)

Cost of Revenue

Gross Profit

Selling, General & Admin

Research & Development

Operating Expenses

Other Non Operating Income (Expenses)

-13

-5

Pretax Income

-38

-29

-11

-4

-14

Income Tax Expense

Net Income

-38

-29

-11

-4

-14

Net Income Growth

-31%

107%

10%

-82%

-188%

27%

Shares Outstanding (Diluted)

54.91

54.89

51.48

54.76

35.59

Shares Change (YoY)

54%

71%

72%

88%

23%

EPS (Diluted)

-0.7

-0.53

-0.2

-0.09

0.13

-0.4

EPS Growth

-55%

34%

-38%

-87%

-148%

Free Cash Flow

-38

-10

-8

-5

Free Cash Flow Per Share

Gross Margin

Operating Margin

Profit Margin

Free Cash Flow Margin

EBITDA

-47

-15

-12

-11

-8

EBITDA Margin

D&A For EBITDA

EBIT

-47

-15

-12

-11

-8

EBIT Margin

Effective Tax Rate

Follow-Up Questions

What are Candel Therapeutics Inc's key financial statements?



According to the latest financial statement (Form-10K), Candel Therapeutics Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for CADL?



Candel Therapeutics Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Candel Therapeutics Inc's revenue broken down by segment or geography?



Candel Therapeutics Inc largest revenue segment is Medical Imaging Services, at a revenue of 627,215,000 in the most earnings release.For geography, Australia is the primary market for Candel Therapeutics Inc, at a revenue of 569,286,000.

Is Candel Therapeutics Inc profitable?



no, according to the latest financial statements, Candel Therapeutics Inc has a net loss of $0

Does Candel Therapeutics Inc have any liabilities?



no, Candel Therapeutics Inc has liability of 0

How many outstanding shares for Candel Therapeutics Inc?



Candel Therapeutics Inc has a total outstanding shares of 0

Candel Therapeutics Inc (CADL) Financial

CADL Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is CADL?

Candel Therapeutics Inc (CADL) Financial

CADL Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is CADL?

CADL Income

Follow-Up Questions

What are Candel Therapeutics Inc's key financial statements?

What are the key financial ratios for CADL?

How is Candel Therapeutics Inc's revenue broken down by segment or geography?

Is Candel Therapeutics Inc profitable?

Does Candel Therapeutics Inc have any liabilities?

How many outstanding shares for Candel Therapeutics Inc?